Lidocaina Cloridrato Galenica Senese (Lidocaine Hydrochloride)

Lidocaine hydrochloride blocks voltage‑gated sodium channels on nerve and cardiac cells, preventing the rapid influx of sodium that initiates action potentials. This reversible blockade stops nerve impulse transmission, producing localized numbness, and can suppress abnormal cardiac electrical activity when given systemically.

The appropriate dose of lidocaine is determined by the prescribing clinician based on the specific procedure, patient weight, age, and clinical condition. Dosing may vary for local infiltration, nerve block, or intravenous anti‑arrhythmic use, and should always follow the prescriber’s instructions.

Safety data for lidocaine during pregnancy and lactation are limited. It is classified as category C, meaning it should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consider possible infant exposure and discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The most common alternative local anesthetic is bupivacaine, which has a longer duration of action but a higher risk of cardiotoxicity at comparable doses. Lidocaine offers a shorter onset and duration, making it suitable for procedures requiring rapid recovery, while bupivacaine is preferred when prolonged anesthesia is needed.

Lidocaina Cloridrato should be stored below 25 °C in its original packaging, protected from light and moisture. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration and discard if any abnormalities are observed.

The product is administered by a qualified healthcare professional via intramuscular or intravenous injection. The injection site and technique depend on the intended use—local infiltration for minor procedures, regional nerve block for targeted anesthesia, or slow intravenous infusion for cardiac arrhythmia control.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias such as ventricular tachycardia, and central nervous system toxicity leading to seizures. Immediate medical attention is required if any of these events occur during or after administration.

Lidocaine is contraindicated in patients with known hypersensitivity to amide‑type local anesthetics, those with severe heart block or uncontrolled arrhythmias, and individuals with significant hepatic impairment that could impair drug metabolism. Caution is also advised for patients with epilepsy or other seizure disorders.